Project Details
Short title | An open label, phase IIa, safety study of the active implantable (radiological) medical device 32P BioSilicon, administered intratumourally to patients with advanced, unresectable pancreatic cancer, in addition to standard intravenous Gemci |
---|---|
Status | Finished |
Effective start/end date | 1/07/07 → 31/10/08 |
Funding
- Queen Elizabeth Hospital